The present disclosure provides methods and related compositions that incorporate a molecularly targeted approach via the integrin subtype αvβ6 using Peptide Receptor Radionuclide Therapy (PRRT) and a theranostic approach.
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
A61K 47/60 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un composé organique macromoléculaire, p.ex. une molécule oligomérique, polymérique ou dendrimérique obtenu par des réactions autres que celles faisant intervenir uniquement des liaisons non saturées carbone-carbone, p.ex. polyurées ou polyuréthanes le composé organique macromoléculaire étant un oligomère, un polymère ou un dendrimère de polyoxyalkylène, p.ex. PEG, PPG, PEO ou polyglycérol
Broadly applicable and stereoselective formation of glycosidic linkage remains challenging yet of critical importance in giycoscience. By developing an SN2 glycosylation, this work advances a general solution to this challenge via stereoinversion at the anomeric position of glycosyl ester donors. This SN2 process is enabled by a basic directing-group in the leaving-group, which is activated by a cationic gold catalyst or any other electrophilic reagent. Unlike all the reported directing group approaches, this strategy is applicable to any glycosyl donors—a long sought-after yet unmet goal in carbohydrate chemistry; moreover, the basic directing-group upon glycosylation is lost as part of the leaving-group and hence traceless in the glycoside products, therefore avoiding potential complications in downstream transformations. Highly selective construction of glycosidic bonds including challenging 1,2-cis glycosidic bonds is achieved in excellent yields. The strategy is applied iteratively to access oligosaccharides and can distinguish alcohols with different steric hindrance.
The present invention is based, in part, on cancer vaccine compositions or pharmaceutical compositions comprising cancer cells, monocytes, and/or osteoclasts that activate NK cells, and methods for using same to prevent and/or treat diseases such as cancer.
The present invention relates to diarylhydantoin compounds, including diarylthiohydantoins, and methods for synthesizing them and using them in the treatment of hormone refractory prostate cancer.
C07D 235/02 - Composés hétérocycliques contenant des cycles diazole-1, 3 ou diazole-1, 3 hydrogéné, condensés avec d'autres cycles condensés avec des carbocycles ou avec des systèmes carbocycliques
C07D 233/74 - Deux atomes d'oxygène, p.ex. hydantoïne avec uniquement des atomes d'hydrogène ou des radicaux ne contenant que des atomes d'hydrogène et de carbone, liés aux autres chaînons du cycle
C07D 233/86 - Atomes d'oxygène et de soufre, p.ex. thiohydantoïne
Techniques for using a shared channel in data communications networks include observing at a local node, during a frame of multiple transmission slots, packets transmitted. Based on the packets, a node identifier and transmission slot are determined for each node in a contention set. A priority for each node in the contention set is determined based on the identifier. When the local node is new to the shared channel, a transmission key is determined for the local node, which indicates a subset of transmission slots in the frame based on the identifier for the local node. When the local node is still new, it transmits a packet only when a current transmission slot is indicated by the transmission key. If not new and with carrier sensing, transmission is delayed even when the priority for the local node in the current time slot is greater than any other.
A cabin air filtration system and method for regenerating a cabin air filtration system are disclosed. The filtration system includes a frame, and a renewable sorption layer within the frame, the renewable sorption layer configured to clean air from one or more of outside of an automobile and inside an automobile. The cabin air filtration system for an automobile can include a first layer, the first layer configured to particulates, and a second layer, the second layer configured to remove volatile compounds and gases. The method includes placing a renewable sorption layer within a frame in an oven, the renewable sorption layer configured to filter air from one or more of outside of the automobile and inside the automobile; creating a vacuum within the oven; and heating a source of water within the oven to perform a steam regeneration treatment on the renewable sorption layer.
B01D 46/10 - Séparateurs de particules utilisant des plaques, des feuilles ou des tampons filtrants à surface plane, p.ex. appareils de précipitation de poussières
B01D 41/00 - Régénération, à l'extérieur du filtre, de la substance filtrante ou des éléments filtrants utilisés dans la filtration des fluides liquides ou gazeux
7.
FERROELECTRIC FIELD-EFFECT TRANSISTOR WITH HIGH PERMITTIVITY INTERFACIAL LAYER
A ferroelectric field-effect transistor having an endurance exceeding 1012 cycles is disclosed. The ferroelectric field-effect transistor includes a substrate, a source disposed over a first region of the semiconductor substrate, a drain disposed over a second region of the substrate, wherein the second region is spaced apart from the first region. The ferroelectric field-effect transistor includes a channel made of a semiconductor material within a third region of the substrate that is between the first region and the second region. The ferroelectric field-effect transistor further includes a gate stack having an interfacial layer disposed over the channel, wherein the interfacial layer has a permittivity that is greater than 3.9, and a layer of ferroelectric material disposed over the interfacial layer.
H01L 29/78 - Transistors à effet de champ l'effet de champ étant produit par une porte isolée
H10B 51/30 - Dispositifs de RAM ferro-électrique [FeRAM] comprenant des transistors ferro-électriques de mémoire caractérisés par la région noyau de mémoire
A method of sensing motion in an MRI scanner includes transmitting at least two tones having different frequencies, using intermodulation to combine the two tones, transmitting the two tones as a combined signal during an MRI scan of a patient, receiving the combined signal using a receiver in the MRI scanner, demodulating the combined signal to produce a demodulated signal, and analyzing the demodulated signal to detect motion of the patient during the MRI scan.
G01R 33/565 - Correction de distorsions d'image, p.ex. dues à des inhomogénéités de champ magnétique
G01R 33/36 - Systèmes d'excitation ou de détection, p.ex. utilisant des signaux radiofréquence - Détails électriques, p.ex. adaptations ou couplage de la bobine au récepteur
9.
METHODS AND COMPOSITIONS FOR IMPROVING PROTEIN HYDROLYSIS
The present disclosure provides food supplements comprising proteases that can digest a variety of food proteins to enhance their protein bioavailability in the gut.
The invention provides new materials and associated methods that are designed to address certain complex biological phenomena associated with pathologies such as cancer. In this context, embodiments of the invention disclosed herein can provide a multimodal, multitemporal approach to cancer therapy by, for example, targeting selected tumor vessels using materials designed deliver antineoplastic agents as well as anti-angiogenic agents, immunotherapeutic agents, and/or imaging agents, in a temporally controlled fashion.
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK (USA)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventeur(s)
Greene, Lloyd, A.
Zhou, Qing
Angelastro, James, M.
Abrégé
Truncated dominant negative forms of CEBPB and CEBPD, and cell-penetrating forms thereof are described. Methods for using the truncated dominant negative forms of CEBPB and CEBPD proteins, and cell-penetrating forms thereof, for decreasing viability of neoplastic cells and treating cancer in a subject are also described.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
A61K 38/16 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés
12 2 is 4-ferrocenylphenyl. Non-aqueous redox flow batteries and electrical energy storage systems comprising the Fe-substituted organometallic complexes and methods of storing energy using the Fe-substituted organometallic complexes are provided.
H01M 4/52 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques de nickel, de cobalt ou de fer
H01M 4/02 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif
H01M 4/36 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs
H01M 4/13 - PROCÉDÉS OU MOYENS POUR LA CONVERSION DIRECTE DE L'ÉNERGIE CHIMIQUE EN ÉNERGIE ÉLECTRIQUE, p.ex. BATTERIES Électrodes Électrodes composées d'un ou comprenant un matériau actif Électrodes pour accumulateurs à électrolyte non aqueux, p.ex. pour accumulateurs au lithium; Leurs procédés de fabrication
THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF VETERANS AFFAIRS (USA)
Inventeur(s)
John, Varghese
Hinman, Jason D.
Jagodzinska, Barbara
Johnson-Cohn, Samuel Whitaker
Campagna, Jesus J.
Abrégé
The present disclosure relates to compounds of formula (I) and compositions comprising the same. The disclosure further relates to methods of treating cognitive impairment.
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p.ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
14.
MOLECULAR GLUE DEGRADER COMPOUNDS AND USES THEREOF
Described herein are molecular glue degrader compounds that bind to both a target protein and a RING E3 Ubiquitin Ligase, as well as related compositions and methods of use, e.g., for degradation of the target protein and/or the treatment of a disease, disorder, or condition.
A61K 31/551 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole ayant deux atomes d'azote comme hétéro-atomes d'un cycle, p.ex. clozapine, dilazèpe
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
15.
IMPLANTABLE AND NON-INVASIVE STIMULATORS FOR GASTROINTESTINAL THERAPEUTICS
Systems and methods for implementation of a disposable miniaturized implant for treatment of Post-Operative Ileums (POI), a miniaturized implant for treating chronic GI dysmotility (e.g., dysphagia, gastroesophageal reflux disease (GERD), nausea, functional dyspepsia, blockage of transit, and gastroparesis, inflammatory bowel disease) and obesity, by providing electrical stimulation to the part of bowel going through surgery to expedite the healing process while recording the smooth muscle activities simultaneously, or providing stimulation on a treatment location of the GI tract or the branch of the vagus nerve. Systems and methods are also provided for non-invasive, transcutaneous stimulation of anatomy within the abdomen of the patient.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
16.
POINT-OF-USE SYSTEM AND METHOD FOR IDENTIFYING COMPONENTS OF AN UNKNOWN DRUG SAMPLE
A point-of-use method for identifying one or more components of an unknown drug sample includes electrochemically analyzing the unknown drug sample to obtain an electrochemical measurement, identifying the components of the unknown drug sample by inputting the electrochemical measurement into a machine learning model trained to identify the components based on the electrochemical measurement, and outputting a listing of the components. A point-of-use system for identifying one or more components of an unknown drug sample includes an electrochemical analyzer configured to receive a quantity of the unknown drug sample and conduct an electrochemical analysis to obtain an electrochemical measurement, a non-transitory storage memory storing a machine learning model trained to identify the components based on the electrochemical measurement, and one or more processors in communication with the electrochemical analyzer and configured to input the electrochemical measurement into the machine learning model and output a listing of the components.
A deep learning-based digital staining method and system are disclosed that enables the creation of digitally/virtually-stained microscopic images from label or stain-free samples based on autofluorescence images acquired using a fluorescent microscope. The system and method have particular applicability for the creation of digitally/virtually-stained whole slide images (WSIs) of unlabeled/unstained tissue samples that are analyzes by a histopathologist. The methods bypass the standard histochemical staining process, saving time and cost. This method is based on deep learning, and uses, in one embodiment, a convolutional neural network trained using a generative adversarial network model to transform fluorescence images of an unlabeled sample into an image that is equivalent to the brightfield image of the chemically stained-version of the same sample. This label-free digital staining method eliminates cumbersome and costly histochemical staining procedures and significantly simplifies tissue preparation in pathology and histology fields.
G06V 10/764 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant la classification, p.ex. des objets vidéo
G06V 10/82 - Dispositions pour la reconnaissance ou la compréhension d’images ou de vidéos utilisant la reconnaissance de formes ou l’apprentissage automatique utilisant les réseaux neuronaux
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p.ex. DICOM, HL7 ou PACS
G16H 30/40 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le traitement d’images médicales, p.ex. l’édition
G16H 70/60 - TIC spécialement adaptées au maniement ou au traitement de références médicales concernant des pathologies
18.
MULTI-HUNDRED OR THOUSAND CHANNEL ELECTRODE ELECTROPHYSIOLOGICAL ARRAY AND FABRICATION METHOD
A flexible electrode array with hundreds or thousands channels for clinical use includes an array of at least hundreds of electrodes on a flexible biocompatible polymer substrate. Perfusion through holes are provided through the substrate. Individual elongate leads connect to each of the electrodes, the elongate lead connections being supported by the flexible biocompatible polymer substrate and extending away from the array. Flexible biocompatible polymer insulates the individual elongate lead connections and supporting the array. An interposer with individual channel connections is conductively bonded to the individual elongate lead connections. Sterile bag packaging encloses a portion of the interposer, where the outer side of the package including the array and individual elongate lead is sterile while the inner side of the packaging is non-sterile. The portion interposer inside the package is configured to connect to a circuit board within the packaging.
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61N 1/05 - Electrodes à implanter ou à introduire dans le corps, p.ex. électrode cardiaque
H05K 1/11 - Eléments imprimés pour réaliser des connexions électriques avec ou entre des circuits imprimés
H05K 1/18 - Circuits imprimés associés structurellement à des composants électriques non imprimés
H05K 3/32 - Connexions électriques des composants électriques ou des fils à des circuits imprimés
19.
HIGH EFFECTIVE REFRACTIVE INDEX MATERIALS FOR ULTRA-HIGH RESOLUTION ILLUMINATION NANOSCOPY
A high effective refractive index structure may include one or more high effective refractive index materials disposed on a substrate. The high effective refractive index structure configured to respond to a light received at the high effective refractive index structure by at least generating one or more sub-diffraction limit illumination patterns for illuminating a specimen while one or more frames are captured of the illuminated specimen. The one or more sub-diffraction limit illumination patterns may include one or more speckle patterns. The one or more high effective refractive index materials may exhibit an effective refractive index equal to or greater than 3. Examples of high effective refractive index materials include hyperbolic metamaterial (HMM) multilayers, nanowire based hyperbolic metamaterials, and organic hyperbolic materials (OHM).
G02B 1/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques
G02B 21/36 - Microscopes aménagés pour la photographie ou la projection
20.
CONDITIONAL DEGRADATION OF PROTEINS THAT ARE LOCALIZED AT THE PLASMA MEMBRANE
Provided herein is a fusion protein comprising: (a) an extracellular domain comprising a first binding moiety that is capable of specifically binding to a first cell surface marker: (b) a transmembrane domain: and (c) an intracellular domain comprising: i. a first dimerization domain that specifically binds to a corresponding target dimerization domain in a target protein: and ii. a degradation domain, wherein the degradation domain is a degron or E3 ligase-recruiting domain. Protein circuits. cells and methods that make use of the fusion protein are also provided.
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
21.
EXTRACELLULAR VESICLES DERIVED FROM INDUCED PLURIPOTENT AND EMBRYONIC STEM CELLS, AND METHODS OF USE FOR IMMUNE MODULATION
The present disclosure provides a composition comprising extracellular vesicles (EVs) derived from induced pluripotent stem cells (iPSCs) or embryonic stem cells (ESCs). The present EVs possess immunoregulatory functions that are distinct from those of EVs derived from mesenchymal stem cells. The present EVs can be used to treat or modulate immune responses in diseases such as cancer or autoimmune diseases.
Virtual and augmented reality devices and methods are provided for measuring and controlling an electrical activity of the brain, including for manipulation of cortico-hippocampal rhythms to treat neurological and neuropsychiatric disorders.
Multi-molecular hyperspectral PRM-SRS imaging technologies advantageously provide faster data processing and direct user-defined visualization with enhanced chemical specificity for distinguishing clinically relevant lipid subtypes in different organs and species. PRM-SMS may include quantifying the spectral similarity between an image pixel spectrum and a known reference spectrum.
Systems and methods for electrochemical hydrogen looping cells are described. Generating a pH swing can expedite carbon dioxide capture from oceanwater. Many embodiments implement electrochemical hydrogen looping cells that simultaneously produce acid via anodic hydrogen oxidation and base via cathodic hydrogen evolution to generate a pH change.
C25B 1/04 - Hydrogène ou oxygène par électrolyse de l'eau
C02F 1/461 - Traitement de l'eau, des eaux résiduaires ou des eaux d'égout par des procédés électrochimiques par électrolyse
C25B 9/65 - Dispositifs pour l'alimentation en courant; Connexions d'électrodes; Connexions électriques intercellulaires
C25B 11/032 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par la configuration ou la forme perforées ou foraminées Électrodes poreuses Électrodes à diffusion de gaz
An Adam optimization-based Pointillism Deconvolution (A-PoD) algorithm for quantitatively measuring the nanoscopic co-localization of biomolecules and metabolic dynamics in organelles. The A-Pod algorithm may be applied to an image to generate a series of super resolved images. The A-PoD algorithm may also be used to process cellular images by interpolating cellular images along an optical axis, resampling the cellular images, and optimizing the cellular images with the A-PoD algorithm, where the resulting cellular images are deconvoluted cellular images.
Provided herein are immortalized mesenchymal stem cells comprising a replicating recombinant retrovirus. Methods for treating a cell proliferative disorder using these immortalized mesenchymal stem cells are also provided.
Systems and methods for subgraph matching using active learning in accordance with embodiments of the invention are illustrated. One embodiment includes a method for subgraph matching with active learning. The method includes steps for encoding vertices of a world graph into a plurality of candidate sets, applying a first filter to each of the plurality of candidate sets to reduce the number of candidates in each of the plurality of candidate sets, querying for a template vertex in a corresponding candidate set from the plurality of candidate sets, determining a final candidate matching the corresponding template vertex for each of the plurality of the candidate sets, and returning a number of total queries made.
G06F 18/2323 - Techniques non hiérarchiques basées sur la théorie des graphes, p.ex. les arbres couvrants de poids minimal [MST] ou les coupes de graphes
EphA2 targeting agents developed herein are potent peptide-mimetics with high affinity (Kds 8-20 nanomolar) for the ligand binding domain, called targefrin. Monomeric versions of targefrin act as antagonists while dimeric versions (targefrin-dimer) of the agent cause receptor internalization and degradation via a lysosomal pathway. Hence, targefrin-dimer agents are effective in reducing pro-oncogenic EphA2 levels in cancer cells when used as single agents or in combination with standards of care. Targefrin-dimers can also sensitize cancer cells that developed resistance to EGER or BRAE inhibitors, and potentially other anti-cancer agents. In addition, the dimeric agents can be conjugated with chemotherapy such as paclitaxel to deliver selectively cytotoxic agent to EphA2 expressing cancer cells. Monomeric agents can be linked to chemotherapy via a stable cleavable linker, accumulate the cytotoxic at the tumor, that then would enter the tumor. Novel composition and examples of these applications are reported.
Methods and device configurations are provided for extracting navigation observables from a downlink communications signal. An example method can include performing a generalized likelihood ratio (GLR) operation to estimate a Doppler frequency of a downlink communication signal and selecting at least one active downlink communication source. The method can include performing operations for a sequential detector to detect the presence of multiple LEO satellites on the same channel and provide an estimate of the number of active LEO satellites. A sequential GLR detector estimates the number of LEO satellites along with their Doppler frequencies, and it provides an initial estimate of their unknown timing signals. Configurations are provided for controlling navigation of a device, such as a rover using differential navigation.
41 - Éducation, divertissements, activités sportives et culturelles
Produits et services
Educational services, namely, conducting workshops, seminars, trainings, and classes in the field of data analysis and the distribution of training materials in connection therewith; educational services, namely, conducting workshops, seminars, trainings, and classes in the field of evaluating environmental health information; provision of educational courses relating to data analysis and evaluating environmental health information; providing educational information about data analysis and the evaluation of environmental health information; educational services, namely, providing panel discussions in the field of data analysis and evaluating environmental health information; providing online non-downloadable electronic publications in the nature of books, handbooks, reports, and articles relating to providing information and analysis relating to data analysis and evaluating environmental health information; information, advisory and consultancy services relating to all the aforesaid.
32.
THERAPIES FOR THE TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH ABNORMAL EXPRESSION OF CDKL5 GENE
The disclosure provides methods for rescuing defects caused by abnormal CDKL5 expression in a subject in need thereof, comprising administering to the subject therapeutically effective amount(s) of a hyperpolarization-activated cyclic nucleotide-gated (HCN) channel blocker, a muscarinic receptor inhibitor, a GSK3 inhibitor, a Notch inhibitor and any combination thereof. The disclosure further provides methods for screening candidate drug candidates in a tiered series of assays and models (neurons, CDKL5-mosaic neurospheres, and cortical organoids).
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
A61K 31/4725 - Isoquinoléines non condensées, p.ex. papavérine contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p.ex. morpholine non condensées et contenant d'autres hétérocycles, p.ex. timolol
A61P 25/00 - Médicaments pour le traitement des troubles du système nerveux
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
33.
MULTI-RESONANT SWITCHED CAPACITOR POWER CONVERTER ARCHITECTURE
A switched-capacitor (SC) network in an SC converter is controlled to operate at varying resonant modes to achieve high conversion ratio efficiency, at a low circuit component count. These power converters are suited to numerous application areas including improving energy efficiency of data centers. A family of resonant switched capacitor (SC) converters with multiple operating phases are presented “Multi-Resonant SC Converters”. Described in detail are an 8-to-1 Multi-Resonant-Doubler (MRD) converter and a 6-to-1 Cascaded Series-Parallel (CaSP). The topology of these converters make them amenable to combining like units in parallel toward reaching higher power levels.
H02M 3/07 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu sans transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des résistances ou des capacités, p.ex. diviseur de tension utilisant des capacités chargées et déchargées alternativement par des dispositifs à semi-conducteurs avec électrode de commande
H02M 1/00 - APPAREILS POUR LA TRANSFORMATION DE COURANT ALTERNATIF EN COURANT ALTERNATIF, DE COURANT ALTERNATIF EN COURANT CONTINU OU VICE VERSA OU DE COURANT CONTINU EN COURANT CONTINU ET EMPLOYÉS AVEC LES RÉSEAUX DE DISTRIBUTION D'ÉNERGIE OU DES SYSTÈMES D'ALI; TRANSFORMATION D'UNE PUISSANCE D'ENTRÉE EN COURANT CONTINU OU COURANT ALTERNATIF EN UNE PUISSANCE DE SORTIE DE CHOC; LEUR COMMANDE OU RÉGULATION - Détails d'appareils pour transformation
H02M 3/158 - Transformation d'une puissance d'entrée en courant continu en une puissance de sortie en courant continu sans transformation intermédiaire en courant alternatif par convertisseurs statiques utilisant des tubes à décharge avec électrode de commande ou des dispositifs à semi-conducteurs avec électrode de commande utilisant des dispositifs du type triode ou transistor exigeant l'application continue d'un signal de commande utilisant uniquement des dispositifs à semi-conducteurs avec commande automatique de la tension ou du courant de sortie, p.ex. régulateurs à commutation comprenant plusieurs dispositifs à semi-conducteurs comme dispositifs de commande finale pour une charge unique
34.
FUSED QUARTZ DUAL SHELL RESONATOR AND METHOD OF FABRICATION
A dual-shell architecture and methods of fabrication of fused quartz resonators is disclosed. The architecture may include two encapsulated and concentric cavities using plasma-activated wafer bonding followed by the high-temperature glassblowing. The dual-shell architecture can provide a protective shield as well as a “fixed-fixed” anchor for the sensing element of the resonators. Structures can be instrumented to operate as a resonator, a gyroscope, or other vibratory sensor and for precision operation in a harsh environment. Methods for fabricating a dual-shell resonator structure can include pre-etching cavities on a cap wafer, pre-etching cavities on a device wafer, bonding the device wafer to a substrate wafer to form a substrate pair and aligning and bonding the cap wafer to the substrate pair to form a wafer stack with aligned cavities including a cap cavity and a device cavity. The wafer stack may be glassblown to form a dual-shell structure.
G01C 19/5719 - Dispositifs sensibles à la rotation utilisant des masses vibrantes, p.ex. capteurs vibratoires de vitesse angulaire basés sur les forces de Coriolis utilisant des masses planaires vibrantes entraînées dans une vibration de translation le long d’un axe
B81C 1/00 - Fabrication ou traitement de dispositifs ou de systèmes dans ou sur un substrat
H03H 3/007 - Appareils ou procédés spécialement adaptés à la fabrication de réseaux d'impédance, de circuits résonnants, de résonateurs pour la fabrication de résonateurs ou de réseaux électromécaniques
The present invention provides methods for guiding preservation of human neurons or human nerves during surgery by administering a fluorescently-labeled peptide that specifically binds to the human neurons or human nerves. The invention further provides human neuron or nerve targeting molecules comprising fluorescently-labeled peptides that specifically bind to human neurons or human nerves and compositions thereof.
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C07K 7/00 - Peptides ayant de 5 à 20 amino-acides dans une séquence entièrement déterminée; Leurs dérivés
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
36.
System and Method for Concurrent X-Nuclei and H-Nuclei Magnetic Resonance Imaging
A method for generating magnetic resonance (MR) images of a kidney region or a brain of a subject using multinuclear magnetic resonance imaging MRI includes performing, using an MRI system, an Na-nuclei pulse sequence module to acquire a portion of a first set of MR data from the kidney or brain region of the subject and performing, using the MRI system, an H-nuclei pulse sequence module to acquire a portion of a second set of MR data from the kidney or brain region of the subject. The Na-nuclei pulse sequence module and the H-nuclei pulse sequence module may be repeated in an interleaved manner until acquisition of the first set of MR data and the second set of MR data are complete. The method further includes generating at least one Na-based image using the first set of MR data, generating at least one H-based image using the second set of MR data and displaying one or more of the at least one Na-based image and the at least one H-based image on a display.
G01R 33/561 - Amélioration ou correction de l'image, p.ex. par des techniques de soustraction ou d'établissement de moyenne par réduction du temps de balayage, c.à d. systèmes d'acquisition rapide, p.ex. utilisant des séquences d'impulsions écho-planar
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/055 - Détection, mesure ou enregistrement pour établir un diagnostic au moyen de courants électriques ou de champs magnétiques; Mesure utilisant des micro-ondes ou des ondes radio faisant intervenir la résonance magnétique nucléaire [RMN] ou électronique [RME], p.ex. formation d'images par résonance magnétique
A magnetic field sensor which can achieve sensitivities competitive with modern sensors while simultaneously maintaining a small size, low power consumption, simplicity of design, and low cost. The magnetic field sensor utilizes nonlinear precession dynamics of subatomic spins to attain parametric amplification of a magnetic field. A preliminary experimental implementation of the proposed concept establishes its feasibility and can already demonstrate significant benefits over existing approaches to sensing.
G01R 33/24 - Dispositions ou appareils pour la mesure des grandeurs magnétiques faisant intervenir la résonance magnétique pour la mesure de la direction ou de l'intensité de champs magnétiques ou de flux magnétiques
38.
Kaposi's Sarcoma Associated Herpesvirus Vaccine and Methods of Making and Using Thereof
A61K 39/245 - Herpetoviridae, p.ex. virus de l'Herpès simplex
A61K 39/39 - Préparations médicinales contenant des antigènes ou des anticorps caractérisées par les additifs immunostimulants, p.ex. par les adjuvants chimiques
C07K 16/08 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant de virus
C07K 14/47 - Peptides ayant plus de 20 amino-acides; Gastrines; Somatostatines; Mélanotropines; Leurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
C07K 16/22 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
C12N 15/11 - Fragments d'ADN ou d'ARN; Leurs formes modifiées
An anode in an electrochemical cell includes an anode active material comprising sodium and a solid electrolyte interphase (SEI) layer disposed on the anode active material. The SEI layer includes reduction products of an electrolyte solvent and is free of degradation products derived from dissolved anions of an electrolyte salt. The electrolyte solvent and the electrolyte salt are present in an electrolyte of the electrochemical cell. The SEI layer does not include a fluorine content greater than 5 wt. %.
The present disclosure provides a composition comprising a solid support, a plurality of tethered oligonucleotides attached to the solid support, and a plurality of untethered oligonucleotides hybridized to the tethered oligonucleotides. An untethered oligonucleotide can comprise, attached via the 5′ end, a cell, or an effector molecule. Hybridization of an untethered oligonucleotide to a tethered oligonucleotide generates an enzyme cleavage site, which allows for temporally controlled removal of an effector molecule. The present disclosure provides methods of temporally modulating the activity and/or phenotype of a cell. The present disclosure provides a solid support comprising patterned tethered oligonucleotides attached thereto; and methods of making the solid support.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
Grow gallium-containing semi-conductor layers are grown on a substrate, wherein the gallium-containing semiconductor layers comprise AlxGayInzNvPwAsu, where 0≤x≤1, 0≤y≤1, 0≤z≤1, 0≤v≤1, 0≤w≤1, 0≤u≤1, v+w+u=1, and x+y+z=1. Dry etching of the gallium-containing semiconductor layers exposes sidewalls of the layers. Surface treatments are performed to recover from damage to the sidewalls resulting from the dry etching. Dielectric materials are deposited on the sidewalls, for example, by atomic layer deposition (ALD), to passivate the sidewalls. The resulting gallium-containing semiconductor layers have an improvement in optical efficiency as compared to gallium-containing semiconductor layers that are not subjected to the surface treatments and the deposition of the dielectric materials.
H01L 33/00 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails
H01L 33/32 - Matériaux de la région électroluminescente contenant uniquement des éléments du groupe III et du groupe V de la classification périodique contenant de l'azote
H01L 33/44 - DISPOSITIFS À SEMI-CONDUCTEURS NON COUVERTS PAR LA CLASSE - Détails caractérisés par les revêtements, p.ex. couche de passivation ou revêtement antireflet
43.
SYSTEMS AND METHODS FOR MAGNETIC RESONANCE BASED RECONSTRUCTION AND TOMOGRAPHY OF ELECTRICAL PROPERTIES
A method can include providing a first neural network connected to a second neural network. The first neural network can represent B+11 and the second neural network can represent electrical properties. The method can include training the first neural network and the second neural network jointly. The method can include determining, from the trained first neural network and the trained second neural network B+11, a prediction of and electrical properties at one or more predetermined locations. The method can include outputting the prediction of B+11 and EP.
Methods and apparatus for dispensing droplets. In accordance with an implementation, an apparatus includes a dispenser, a liquid source, and a pressure source. The dispenser includes a tube having an outlet, a channel surrounding the tube, a flow path coupling the channel and the outlet of the tube. The liquid source to be coupled to the tube and to contain a liquid and the pressure source to be coupled to the channel. The liquid is to flow from the liquid source through the tube and the pressure source is to flow gas through the channel to cause a droplet of the liquid to be dispensed from the outlet of the tube.
B29C 64/106 - Procédés de fabrication additive n’utilisant que des matériaux liquides ou visqueux, p.ex. dépôt d’un cordon continu de matériau visqueux
The shallow neural network with multiple recurrent and redundant loop-like wave mediated neuronal connections employs amplitude weighting factors and a phase parameter represented by non-planar connection paths. The presence of non-planarity in the connection paths allows faster and more efficient computations, reduced memory demands, and enhanced learning capabilities compared to traditional multi-layer deep AI/ML neural networks.
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/517 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des systèmes carbocycliques, p.ex. quinazoline, périmidine
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p.ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p.ex. azélastine, pentylènetétrazole
Disclosed herein are systems, compositions and methods for using a split dCas protein system to modify the epigenetic profile of a gene of interest. The systems, compositions, and methods are useful for modifying the epigenetic profile of a particular gene within a cell, based on the discovery that effective expression of a larger-sized recombinant protein can be successfully achieved using two separate expression cassettes each encoding a half of the protein fused with a half of an intein, utilizing the unique feature of an intein system to ultimately rejoin the two halves to form one larger fusion protein with the intein spliced out.
A61K 48/00 - Préparations médicinales contenant du matériel génétique qui est introduit dans des cellules du corps vivant pour traiter des maladies génétiques; Thérapie génique
A detector module is provided that can be used as part of a time-of-flight positron emission tomography (TOF-PET) system. The detector module comprises a plurality of emitter elements, each emitter element including an emitter composed of a substance that produces scintillation light and/or Cherenkov radiation in response to gamma photons and, coupled to each of two opposing ends of the emitter, a plurality of photodetectors. The height or thickness of the emitters between their coupled photodetectors is less than 20 mm (e.g., 5-15 mm). The photomultipliers may be silicon photomultipliers or SiPMs that have surface areas less than approximately 9 mm2. Due to the quantity of photodetectors, their operating locations at both ends of each emitter, and the relative thinness of the emitters, the emitter elements and the detector module provide a timing resolution better (lower) than 100 ps full width at half maximum.
G01T 1/29 - Mesure effectuée sur des faisceaux de radiations, p.ex. sur la position ou la section du faisceau; Mesure de la distribution spatiale de radiations
The present disclosure provides methods for producing fuels, such as biofuels, and commodity chemicals. In some embodiments, the methods comprise pretreating cellulosic biomass with a sugar acid. In some embodiments, the methods further comprise recycling sugar acids that are produced during fermentation for use in the subsequent pretreatment of cellulosic biomass. In some embodiments, the methods further comprise utilizing one or more components produced during pretreatment for subsequent fermentation. Fuels and commodity chemicals produced according to the methods of the present invention are also provided herein.
C12P 7/10 - Ethanol en tant que produit chimique et non en tant que boisson alcoolique préparé comme sous-produit, ou préparé à partir d'un substrat constitué par des déchets ou par des matières cellulosiques d'un substrat constitué par des matières cellulosiques
C12P 1/02 - Préparation de composés ou de compositions, non prévue dans les groupes , utilisant des micro-organismes ou des enzymes; Procédés généraux de préparation de composés ou de compositions utilisant des micro-organismes ou des enzymes utilisant des champignons
50.
MULTI-WAVELENGTH STRUCTURED LIGHT CAMERA SYSTEM FOR PRECISION POSITIONING AND QUALITY CONTROL
This disclosure provides a precision-positioning/quality control system capable of measuring the exact position of any given mechanical component/part of any size or shape used during an assembly process. In one aspect, a process for performing high-accuracy localization and positioning of a rigid object is disclosed. This process can begin by receiving a full image of the object. The full image is then processed by a deep-learning module to identify a set of regions of interest on the object. Next, the identified regions in the set of regions of interest are subsequently processed to identify a number of surface points within each identified region and accurately estimate their positions. After sequentially processing all the regions of interest, the process subsequently generates an accurate position estimation for the object based on the combined set of identified high-precision surface points for the set of regions of interest.
G06V 10/25 - Détermination d’une région d’intérêt [ROI] ou d’un volume d’intérêt [VOI]
H04N 23/13 - Caméras ou modules de caméras comprenant des capteurs d'images électroniques; Leur commande pour générer des signaux d'image à partir de différentes longueurs d'onde avec plusieurs capteurs
H04N 23/69 - Commande de moyens permettant de modifier l'angle du champ de vision, p. ex. des objectifs de zoom optique ou un zoom électronique
H04N 23/695 - Commande de la direction de la caméra pour modifier le champ de vision, p. ex. par un panoramique, une inclinaison ou en fonction du suivi des objets
H04N 23/698 - Commande des caméras ou des modules de caméras pour obtenir un champ de vision élargi, p. ex. pour la capture d'images panoramiques
51.
METHODS AND SYSTEMS OF PREDICTING AGENT INDUCED EFFECTS IN SILICO
The disclosure presents a new computer based model framework to predict drug effects over multiple time and spatial scales from the drug chemistry to the cardiac rhythm. The disclosure presents a new computer based model framework to predict drug effects from the level of the receptor interaction to the cardiac rhythm.
G16C 20/30 - Prévision des propriétés des composés, des compositions ou des mélanges chimiques
G16C 20/70 - Apprentissage automatique, exploration de données ou chimiométrie
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
Provided are methods of modulating gene expression levels in an individual identified as having endometriosis. The methods comprise administering to the individual identified as having endometriosis a drug described herein in an amount effective to modulate gene expression levels in the individual. Also provided are pharmaceutical compositions. The compositions comprise a drug described herein in an amount effective to modulate gene expression levels in an individual, wherein the pharmaceutical composition is adapted for intrauterine or intravaginal administration of the drug to the individual. Kits that find use in practicing the methods of the present disclosure are also provided. In some embodiments, the kits comprise a pharmaceutical composition comprising a drug described herein in an amount effective to modulate gene expression levels in the individual, and instructions for administering the pharmaceutical composition to an individual identified as having endometriosis.
A method of treating an ocular disorder in a subject in need thereof includes administering to the subject a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt, tautomer, or solvate thereof.
The present disclosure provides methods and compositions for increasing resistance of plants to a disease caused by infection with bacteria of a Liberibacter species.
National Technology & Engineering Solutions of Sandia, LLC (USA)
Inventeur(s)
Cates, Joshua W.
Choong, Woon-Seng
Brubaker, Erik
Abrégé
A single photon radiation detector is designed for a particular radiation source fluence, such that an incident radiation photon strikes a scintillator monolith, creating scintillation photons, which are amplified by appropriately sized channels of photomultipliers optically coupled to the scintillator monolith. The photomultiplier output is electronically shaped into a corresponding stream of scintillation pulses (otherwise referred to as scintillation photons) that pass through a comparator to produce a bitstream of the detected scintillation photons, which is sampled into a field programmable gate array (FPGA) acting as a giga-sample transceiver to produce time-to-digital conversions, capable of producing an output data stream of 10's-of-giga-samples per second or more. Appropriate design ensures sparsity of scintillation photon arrival, so that each photon in the bitstream corresponds to a single incident scintillation photon.
Systems and methods for electrochemical hydrogen looping cells are described. Generating a pH swing can expedite carbon dioxide capture from oceanwater. Many embodiments implement electrochemical hydrogen looping cells that simultaneously produce acid via anodic hydrogen oxidation and base via cathodic hydrogen evolution to generate a pH change.
C25B 9/19 - Cellules comprenant des électrodes fixes de dimensions stables; Assemblages de leurs éléments de structure avec des diaphragmes
C25B 11/032 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Électrodes; Leur fabrication non prévue ailleurs caractérisées par la configuration ou la forme perforées ou foraminées Électrodes poreuses Électrodes à diffusion de gaz
C25B 13/04 - PROCÉDÉS ÉLECTROLYTIQUES OU ÉLECTROPHORÉTIQUES POUR LA PRODUCTION DE COMPOSÉS ORGANIQUES OU MINÉRAUX, OU DE NON-MÉTAUX; APPAREILLAGES À CET EFFET Éléments d'espacement caractérisés par le matériau
C25B 9/65 - Dispositifs pour l'alimentation en courant; Connexions d'électrodes; Connexions électriques intercellulaires
C25B 9/77 - Assemblages comprenant plusieurs cellules du type filtre-presse avec diaphragmes
A skin-covered, linkage-driven implantable prosthesis, the prosthesis comprising a first linkage comprising a distal end and a proximal end, wherein the proximal end is configured to fixate into a first proximal bone and comprises a first hinge configured to rotate in parallel with a first proximal joint, a second linkage with a hollow center to configured to allow the first linkage to cross through and comprising a distal end and a proximal end, wherein the proximal end is configured to fixate into a second proximal bone, a second hinge attached to distal end of the first linkage and configured to imitate a second proximal joint, and a tip component configured to imitate a distal phalanx and connected to the first linkage by the second hinge and to the second linkage by a bottom hinge, wherein motion of the prosthesis is allowed through a linkage- driven mechanism.
The present invention relates to the development of and use of genetically modified human differentiated cells coupled with xenotransplantation into animal models to identify injury and disease-specific RNA and/or protein biomarkers. Specifically, the present invention encompasses two complementary methods for biomarker discovery that enable the direct and selective labelling, isolation, and analysis of human-specific RNA and/or proteins from xenotransplantation (or chimeric) animal models. Both methods involve the treatment of animal models with an RNA analog and/or amino acid analog that enables the specific isolation and quantification of human RNAs and/or proteins for the identification of novel human biomarkers for a large array of human injuries and diseases.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A01K 67/0271 - Vertébrés chimériques, p. ex. comprenant des cellules exogènes
There are provided, inter alia, compositions and methods for treatment of cancer. The methods include administering to a subject in need a therapeutically effective amount of a Bruton's tyrosine kinase (BTK) antagonist and a ROR-1 antagonist. Further provided are pharmaceutical compositions including a BTK antagonist, ROR-1 antagonist and a pharmaceutically acceptable excipient. In embodiments, the BTK antagonist is ibrutinib and the ROR-1 antagonist is cirmtuzumab.
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 31/519 - Pyrimidines; Pyrimidines hydrogénées, p.ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p.ex. composés antiphlogistiques et pour le cœur
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
61.
FAST DIAGNOSIS AND PERSONALIZED TREATMENTS FOR ACNE
Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.
C12Q 1/689 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour la détection ou l’identification d’organismes pour les bactéries
C12N 7/00 - Virus, p.ex. bactériophages; Compositions les contenant; Leur préparation ou purification
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
C12Q 1/70 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismes; Compositions à cet effet; Procédés pour préparer ces compositions faisant intervenir des virus ou des bactériophages
62.
Wireless Recording System-on-chip for Distributed Neural Interface Systems with Inductive Power Delivery and UWB Data Transmission
Systems and method for wireless recording system-on-chips for distributed neural interface systems with inductive power delivery and UWB data transmission are described. In an embodiment, the system includes an implantable neural interface including: an electrode array having several electrodes; front end circuitry including: one or more digital components, and at least one amplifier coupled to a first electrode and a second electrode of the electrode array, wherein the amplifier and the first electrode and the second electrode form a sensing channel configured to sense electrical activity; and a transceiver including: several digital components; a power harvesting system that receives RF energy through a wireless power link; and a wireless clock receiver that provides a clock signal to the one or more digital components of the front end circuitry and the several digital components of the transceiver.
A61B 5/293 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électroencéphalographie [EEG] invasives
A61B 5/283 - Détection, mesure ou enregistrement de signaux bioélectriques ou biomagnétiques du corps ou de parties de celui-ci Électrodes bioélectriques à cet effet spécialement adaptées à des utilisations particulières pour l’électrocardiographie [ECG] invasives
A61N 1/36 - Application de courants électriques par électrodes de contact courants alternatifs ou intermittents pour stimuler, p.ex. stimulateurs cardiaques
A61N 1/372 - Aménagements en relation avec l'implantation des stimulateurs
H02J 50/00 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique
H02J 50/10 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant un couplage inductif
H02J 50/20 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant des micro-ondes ou des ondes radio fréquence
H02J 50/40 - Circuits ou systèmes pour l'alimentation ou la distribution sans fil d'énergie électrique utilisant plusieurs dispositifs de transmission ou de réception
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, A CALIFORNIA CORPORATION (USA)
Inventeur(s)
Roth, Theodore Lee
Marson, Alexander
Abrégé
Provided herein are methods and compositions for editing the genome of a cell. In some embodiments, a nucleotide sequence of at least 200 nucleotides in length is inserted into a target region in the genome of a cell.
A method includes forming a conductive material on a first dielectric layer, exposing the conductive material to aniline to produce a passivated surface of the conductive material, and after exposing the conductive material to aniline, forming a second dielectric layer on the first dielectric layer using a deposition process. The deposition process is a water-free and plasma-free deposition process, and the second dielectric layer does not form on the passivated surface of the conductive material.
H01L 21/02 - Fabrication ou traitement des dispositifs à semi-conducteurs ou de leurs parties constitutives
H01L 21/67 - Appareils spécialement adaptés pour la manipulation des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide pendant leur fabrication ou leur traitement; Appareils spécialement adaptés pour la manipulation des plaquettes pendant la fabrication ou le traitement des dispositifs à semi-conducteurs ou des dispositifs électriques à l'état solide ou de leurs composants
65.
AUTOMATIC TROUBLESHOOTING SYSTEM FOR USER-LEVEL PERFORMANCE DEGRADATION IN CELLULAR SERVICES
Aspects of the subject disclosure may include, for example, training a cell-level machine learning model to predict a likelihood of a cell site in a cellular network having service issues that impact customers of the cellular network, training a user equipment (UE) level machine learning model using output information from the cell-level machine learning model and historical information about UE-level performance metrics, receiving, from a customer associated with a UE device operating on the cellular network, information about a service degradation experienced by the customer on the UE device, providing the information about the service degradation to the UE-level machine learning model; and receiving, from the UE-level machine learning model, information identifying a source of the service degradation. Other embodiments are disclosed.
H04W 24/04 - Configurations pour maintenir l'état de fonctionnement
H04L 41/149 - Analyse ou conception de réseau pour la prédiction de la maintenance
H04L 41/16 - Dispositions pour la maintenance, l’administration ou la gestion des réseaux de commutation de données, p.ex. des réseaux de commutation de paquets en utilisant l'apprentissage automatique ou l'intelligence artificielle
Aspects of the subject disclosure may include, for example, categorizing users of a cellular network according to a plurality of user categories, identifying, by a machine learning model, a service degradation in the cellular network, identifying at least one affected user, the at least one affected user being affected by the service degradation, identifying one or more affected user categories including the at least one affected user, identifying potentially affected users, the potentially affected users being categorized according to the one or more affected user categories, and taking action to isolate the potentially affected users from the service degradation. Other embodiments are disclosed.
H04W 24/02 - Dispositions pour optimiser l'état de fonctionnement
H04L 41/16 - Dispositions pour la maintenance, l’administration ou la gestion des réseaux de commutation de données, p.ex. des réseaux de commutation de paquets en utilisant l'apprentissage automatique ou l'intelligence artificielle
H04L 41/507 - Filtrage des clients affectés par des problèmes de service
H04W 36/30 - La resélection étant déclenchée par des paramètres spécifiques par des données de mesure ou d’estimation de la qualité des liaisons
67.
GENETICALLY DEFINED IMMUNE-CHECKPOINT INHIBITOR RESISTANCE IN AGGRESSIVE PRECURSORS OF HPV--HEAD AND NECK SQUAMOUS CANCER
Applicant provides herein methods for treating a patient having a pre-cancerous oral leukoplakia (LK) lesion or for delaying the progression of a pre-cancerous oral LK to oral squamous cell carcinoma. It also provides methods to identify patients that more likely to respond to a therapy comprising administration of an effective amount of an anti-PD-1 or anti-PD-L1 therapy.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
Bead constructs of sizes in the nanometer to micrometer range with a primary functionalization of a lipid membrane with embedded anchor peptides are provided. The anchor peptides may be adapted for a secondary functionalization of active molecules that are bound to the anchor peptides by transpeptidation or similar process. The functionalized bead platform can be adaptable and used in many different applications including biochemical and cellular assays, molecular diagnostics such as protein-protein interactions, protein-DNA interactions, DNA detection, separations, purifications, imaging, and microfluidics.
A61K 47/69 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament le conjugué étant caractérisé par sa forme physique ou sa forme galénique, p.ex. émulsion, particule, complexe d’inclusion, stent ou kit
Provided are antibodies that specifically bind to human urokinase-type plasminogen activator receptor (uPAR). In some instances, the antibodies are cross-reactive one or more non-human animal uPAR polypeptides, such as a non-human primate uPAR, e.g., a cynomolgus uPAR. Fusion proteins and conjugates comprising the antibodies of the present disclosure are also provided. Methods of using the antibodies, fusion proteins and conjugates of the present disclosure to treat a condition associated with uPAR expression and/or activity are also provided. In some embodiments, the condition associated with uPAR expression and/or activity is cancer. Non-limiting examples of such cancers include those characterized by cancer cells that express uPAR on the surface thereof, cancers characterized by stromal cells in the tumor microenvironment that express uPAR on the surface thereof, and/or the like.
C07K 14/705 - Récepteurs; Antigènes de surface cellulaire; Déterminants de surface cellulaire
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
Provided herein is a method for evaluating infant suckling behavior, comprising: collecting suckling data from an infant using a vacuum measurement device, transmitting the collected suckling data to a processor, processing the collected suckling data by the processor using a pre-trained Machine Learning (ML) algorithm to identify one or more abnormalities in the infant's suckling behavior, wherein the ML algorithm has been trained on a set of training data comprising a plurality of dimensions associated with the training data, and wherein the identified one or more abnormalities are corresponding to one or more of the plurality of dimensions.
Compositions and methods are described herein that are useful for the detection of prostate cancer progression by determining the expression levels of genes associated with metastatic PCa. Based on the expression of IL-6, SELE, FOSB, NRK, NFKB2, FOXP3, ARG1, CEBPDP, TNFα, ADAMTS4, PENK, FOSL1, DUSP1, ACTA1, AGT, ATF3, CDK1, CXCL8, SELP, VCAN, TFP12, or NR4A3 genes or any combination thereof, treatment of PCa with SELE agonists, TNFα antagonists, and/or immune checkpoint inhibitors (ICIs) are shown to be effective.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
A61K 41/00 - Préparations médicinales obtenues par traitement de substances par énergie ondulatoire ou par rayonnement corpusculaire
72.
CIRCUMVENTING BARRIERS TO HYBRID CROPS FROM GENETICALLY DISTANT CROSSES
CENTRE DE COOPERATION INTERNATIONALE EN RECHERCHE AGRONOMIQUE POUR LE DEVELOPPEMENT (France)
MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E.V. (Allemagne)
Inventeur(s)
Sundaresan, Venkatesan
Khanday, Imtiyaz
Guiderdoni, Emmanuel
Mieulet, Delphine
Mercier, Raphaël
Abrégé
Synthetic apomixis can be achieved in an F1 hybrid of rice by inducing MiMe mutations and egg cell expression of BBM1 in a single step, while simultaneously providing an increased efficiency of clonal seed production. This can be used to generate hybrid plants from crosses from distant subspecies parents that produce clonal seed, allowing for maintenance of heterosis in future generations.
The present disclosure provides compositions and methods for producing a crop plant or seeds of the crop plant that induce biofilm formation (e.g., biofilm comprising nitrogen-fixing bacteria), in which the crop plant or the seeds are treated with a compound of Table 1 (e.g., tannic acid).
Certain embodiments of the invention provide a synthetic genomic safe harbor in the genome of a cell. Certain embodiments provide a method of creating a synthetic genomic safe harbor in a genome. Certain embodiments of the invention provide a method of genome editing in a cell.
C12N 15/85 - Vecteurs ou systèmes d'expression spécialement adaptés aux hôtes eucaryotes pour cellules animales
A61K 31/711 - Acides désoxyribonucléiques naturels, c. à d. contenant uniquement des 2'-désoxyriboses liés à l'adénine, la guanine, la cytosine ou la thymine et ayant des liaisons 3'-5' phosphodiester
75.
TEMPOROMANDIBULAR JOINT REPLACEMENT PROSTHESIS AND METHODS OF USE
Described herein are temporomandibular joint (TMJ) prosthesis (100) designs for use in animals, such as dogs and cats. The prosthesis designs include a cranial component (102) for attachment to a cranium, a mandibular component (108) for attachment to a mandible, and an articulation component. The articulation component includes a ball (116) and socket (124) joint that provides for relative movement between the cranial and mandibular components. Also described are methods of treating a mammal with the TMJ prosthesis designs.
A method includes forming a conductive material on a first dielectric layer, exposing the conductive material to aniline to produce a passivated surface of the conductive material, and after exposing the conductive material to aniline, forming a second dielectric layer on the first dielectric layer using a deposition process. The deposition process is a water-free and plasma-free deposition process, and the second dielectric layer does not form on the passivated surface of the conductive material.
C23C 16/04 - Revêtement de parties déterminées de la surface, p.ex. au moyen de masques
C23C 16/52 - Commande ou régulation du processus de dépôt
C23C 16/18 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c. à d. procédés de dépôt chimique en phase vapeur (CVD) caractérisé par le dépôt d'un matériau métallique à partir de composés organométalliques
C23C 16/455 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c. à d. procédés de dépôt chimique en phase vapeur (CVD) caractérisé par le procédé de revêtement caractérisé par le procédé utilisé pour introduire des gaz dans la chambre de réaction ou pour modifier les écoulements de gaz dans la chambre de réaction
C23C 16/44 - Revêtement chimique par décomposition de composés gazeux, ne laissant pas de produits de réaction du matériau de la surface dans le revêtement, c. à d. procédés de dépôt chimique en phase vapeur (CVD) caractérisé par le procédé de revêtement
Recovering symbols from a stripped binary includes representing the stripped binary as a plurality of graph of graphs (GoG) representations, converting the plurality of GoGs into a plurality of expressive representations of each function in the stripped binary, training a machine learning (ML) model using the expressive representations, and determining a missing symbol of at least one of the functions based on an output of the ML model. Information relating to functions is and interactions between functions are used to train an ML to determine similarity of two functions. Based on similarities, missing symbols may be inferred and used to enable updates to the stripped binary file where source code is not available.
This disclosure provides systems, methods, and apparatus related to an ultrasonic microphone and an ultrasonic acoustic radio. In one aspect a system includes a transmitter and a receiver. The receiver comprises a membrane. The membrane comprises a single layer or multiple layers of a two-dimensional material. The receiver is operable to receive sound waves in a frequency range, with the frequency range being the ultrasonic frequency range.
G01H 11/06 - Mesure des vibrations mécaniques ou des ondes ultrasonores, sonores ou infrasonores par détection des changements dans les propriétés électriques ou magnétiques par des moyens électriques
G01S 15/10 - Systèmes pour mesurer la distance uniquement utilisant la transmission de trains discontinus d'ondes modulées par impulsions
G08B 1/08 - Systèmes de signalisation caractérisés seulement par la forme de transmission du signal utilisant une transmission électrique
Provided herein are, inter alia, antibodies (e.g. humanized antibodies, monoclonal antibodies, antibody fragments (e.g., scFvs) and antibody compositions (e.g., chimeric antigen receptors, bispecific antibodies), which bind human tyrosine kinase-like orphan receptor 1 (ROR1) with high efficiency and specificity. The antibodies and antibody compositions provided herein include novel light and heavy chain domain CDRs and framework regions and are, inter alia, useful for diagnosing and treating cancer and other ROR1-related diseases.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p.ex. les supports ou les additifs inertes; Agents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p.ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p.ex. un fragment Fc
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
A method, a system, an apparatus, and a computer program product for determining a location of a wireless device. One or more second wireless devices in a plurality of second wireless devices are configured for processing one or more communications exchanged with a first wireless device in a plurality of first wireless devices to determine a location of the first wireless device in an environment. One or more communications are processed using one or more second wireless devices. The location of the first wireless device in the environment is determined based on the processed one or more communications.
G01S 5/02 - Localisation par coordination de plusieurs déterminations de direction ou de ligne de position; Localisation par coordination de plusieurs déterminations de distance utilisant les ondes radioélectriques
G01S 5/04 - Position de source déterminée par plusieurs radiogoniomètres espacés
G01S 13/76 - Systèmes utilisant la reradiation d'ondes radio, p.ex. du type radar secondaire; Systèmes analogues dans lesquels des signaux de type pulsé sont transmis
81.
METASURFACE, METALENS, AND METALENS ARRAY WITH CONTROLLABLE ANGULAR FIELD-OF-VIEW
A metalens and a metalens array having a bounded angular field of view are disclosed. The metalens includes a substrate and a two-dimensional (2D) grid over the substrate to divide the substrate into a 2D array of meta-units. Each meta-unit in the 2D array includes a nanostructure and a portion of the substrate that supports the nanostructure. Moreover, each meta-unit is configured with an angular-dependent transmission or reflection coefficient that decreases with an increasing incident angle of an illumination. Moreover, the metalens passes an incident light having an incident angle less than a cutoff angle and rejects an incident light having an incident angle greater than the cutoff angle. The metalens can be used a base unit for constructing a metalens array by tiling copies of the metalens into a 2D array of the metalens to achieve a significantly larger field-of-view.
G02B 1/00 - OPTIQUE ÉLÉMENTS, SYSTÈMES OU APPAREILS OPTIQUES Éléments optiques caractérisés par la substance dont ils sont faits; Revêtements optiques pour éléments optiques
A method, a system, and a computer program product for detecting and/or determining occurrence of a neurological event in a subject. Data corresponding to one or more symptoms, detected by one or more sensors, associated with a subject is received. The sensors include sensors positioned directly on the subject and/or sensors positioned away from the subject. One or more symptom values are assigned to one or more detected symptoms. A severity score for each of the symptoms is determined. The severity scores are determined using one or more machine learning models receiving the assigned symptom values as input. A prediction that the subject is experiencing at least one neurological event and at least a type of the neurological event is generated using a combination of the determined severity scores corresponding to the symptoms. A generation of one or more alerts is triggered based on the prediction. One or more user interfaces are generated for displaying the alerts.
A61B 5/00 - Mesure servant à établir un diagnostic ; Identification des individus
A61B 5/0205 - Evaluation simultanée de l'état cardio-vasculaire et de l'état d'autres parties du corps, p.ex. de l'état cardiaque et respiratoire
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicales; TIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
83.
HTR1F ANTAGONISTS FOR IMPROVEMENT OF BETA CELL SURVIVAL AND FUNCTION
Methods for treating diabetes are described. The methods include administration of a serotonin receptor 1F (HTR1F) antagonist, such as a substituted piperidine, methysergide, or methiothepin, to a subject in need thereof. Administration of the HTR1F antagonist can increase survival of pancreatic beta cells in conjunction with pancreatic islet transplantation. Methods for transplanting pancreatic islets to subjects such as diabetes patients are also described.
The J. Gladstone Institutes, a testamentary trust established under the will of J. David Gladstone (USA)
The Regents of the University of California (USA)
Inventeur(s)
Marson, Alexander
Mamedov, Murad
Abrégé
Described herein are positive and negative regulators of BTN3A, as well as methods for identifying subjects who can benefit from T cell therapies and/or various chemotherapies. The subjects can for example be suffering from immune disorders, cancer and other diseases and conditions.
G01N 33/50 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique
85.
IMMUNE RECEPTORS WITH SYNTHETIC CO-STIMULATORY DOMAINS
An engineered immune receptor (e.g., a chimeric antigen receptor (CAR) or chimeric costimulatory receptor (CCR)) that contains one or more short linear motifs that bind to other intracellular signaling proteins are provided, as well as nucleic acids encoding the same, cells that contain the same and methods of use. Examples of such motifs include a PLCγ1-binding motifs and TRAF binding motifs, but other motifs may be used. These motifs are thought to recruit other proteins to the engineered immune receptor, thereby altering cellular responses.
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
86.
COMPOSITIONS AND METHODS FOR DETECTING PLXDC1 AND PLXCD2 IN HUMAN TISSUES
The present disclosure relates generally to methods for preparing a tissue sample for detection of the expression of a transmembrane protein in the tissue sample. The present disclosure also provides antibodies and treatments targeting tumor samples expressing the PLXDC1 or the PLXDC2 proteins.
G01N 33/574 - Tests immunologiques; Tests faisant intervenir la formation de liaisons biospécifiques; Matériaux à cet effet pour le cancer
C07K 16/28 - Immunoglobulines, p.ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A latent heat battery (LHB) is provided that stores latent heat for on-demand use (e.g., for conversion into electricity) and that cycles through charge and discharge cycles. In the charge cycle, a phase change material or PCM (e.g., silver) residing in an inner chamber of the battery is heated to or beyond its melting temperature, thereby storing latent heat within the battery. Illustratively, the heating may occur by collecting or focusing solar energy, or by powering an internal heater (e.g., a resistance heater). In the discharge cycle, the stored latent heat is extracted as the PCM freezes, through a heat pipe or some other construct that couples the PCM to the environment external to the LHB.
F28D 20/02 - Appareils ou ensembles fonctionnels d'accumulation de chaleur en général; Appareils échangeurs de chaleur de régénération non couverts par les groupes ou utilisant la chaleur latente
H01M 10/6569 - Fluides qui subissent un changement ou une transition de phase liquide-gaz, p.ex. évaporation ou condensation
H01M 50/124 - Boîtiers, fourreaux ou enveloppes primaires d’une seule cellule ou d’une seule batterie caractérisés par le matériau ayant une structure en couches
88.
TECHNIQUES TO PREDICT COMPATIBILITY, APPLICABILITY, AND GENERALIZATION PERFORMANCE OF A MACHINE-LEARNING MODEL AT RUN TIME
basis (additionally applicable on a population level), by analyzing how the machine-learning model responds to the input query, and outputting a prediction of model generalization for the machine-learning model based on the one or more metrics.
A core-shell particle system for performing nucleic acid amplification of targets includes particles having a hydrogel outer shell surrounding a core region that is substantially devoid of hydrogel, wherein the outer shell comprises pores having a size that permit the passage of the targets and nucleic acid reagents into the core region from an external environment surrounding the particles while substantially preventing the escape of amplicons generated in the core region in response to nucleic acid amplification. The system is used by mixing the particles with target and nucleic acid amplification reagents and partitioning the particles from one another. The particles are incubated for a period of time so as to generate amplicons. The particles are then de-partitioned from one another. The de-partitioned particles are then exposed to a dye or fluorescent reporter that is specific to nucleic acids or to a target amplicon and optically interrogated.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c. à d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
91.
SYSTEMS, DEVICES AND METHODS FOR SORTING MOVING PARTICLES
Systems, devices and methods for sorting particles utilizing focus stacking of two-dimensional images are described. Such systems, devices and methods may further provide for particle processing and may encompass, on a microfluidic scale, sample enrichment, sample mixing, sample/particle sorting, verification of sorting and feedback-based optical sorting.
MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCHAFTEN E.V. (Allemagne)
THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (USA)
Inventeur(s)
Panetta, Francis Julian
Babaei, Vahid
Esfahani, Halehossadat Mohammadian
Luci, Emiliano
Prof. Seidel, Hans-Peter
Abrégé
Disclosed herein is a manufacturing system (100, 300). The execution of the machine executable instructions (112) causes a computational system (104) to: receive (200) a release profile (114, 720, 722) for an object to be constructed of one or more materials; construct (202) a similarity cost function (116) dependent on a difference between a simulated release curve (118) of a trial density field (120) and the release profile for the object; construct (204) an optimization problem (122) comprising the similarity cost function and a manufacturing penalty function (124); construct (206) an optimized density field (126) by numerically solving the optimization problem to provide the trial density field that minimizes the optimization problem; and provide (210) a three-dimensional design (130, 730, 732, 734) of the object using the optimized density field that minimizes the optimization problem.
NatureNature 565: 91–95). The parthenogenesis efficiency by BABY BBOM1 itself is 10-29 %. This invention describes methods of high frequency of parthenogenesis by simultaneous expression of BABY BOOM and DWT1 transcription factors. When BABY BOOM1 and DWT1 are expressed together through egg cell-specific promoters, parthenogenesis efficiencies of up to 90 % are achieved. These high parthenogenesis efficiencies are a prerequisite for field applications of synthetic apomixis in crop plants.
This disclosure provides systems, methods, and apparatus related to high-temperature thermal energy storage. In one aspect, a composite material includes a ceramic and graphite flakes dispersed in the ceramic. The ceramic serves as a matrix of the composite material. The ceramic is an oxide, a carbide, a boride, or a nitride. The graphite flakes are about 20 weight % to 35 weight % of the composite material. The composite material has a porosity of about 5% to 40%.
C04B 35/52 - Produits céramiques mis en forme, caractérisés par leur composition; Compositions céramiques; Traitement de poudres de composés inorganiques préalablement à la fabrication de produits céramiques à base de non oxydes à base de carbone, p.ex. graphite
95.
CHROMIUM AND ARSENIC SEPARATIONS USING POROUS ORGANIC FRAMEWORKS
The disclosure provides for porous organic frameworks functionalized to comprise pendant amino-dial groups and/or amino-polyol groups, and uses thereof, including for use in selectively capturing and/or separating anionic contaminants, such as chromium and arsenic oxyanions, including Cr(O), Cr(ll), Cr (III), Cr (IV), and/or Cr (VI), from other components.
Methods for analyzing the metastatic potential of circulating tumor cells (CTCs). Methods including analyzing growth signaling autonomy, methods for determining the likelihood of tumor metastases, and methods of treating a cancer determined to be likely to metastasize.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p.ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
A new prune cultivar designated ‘UC G2S-8’ has been developed. The fruit of this cultivar are medium, yellow in color and covered with a grayish waxy bloom. The ‘UC G2S-8’ tree is productive and a regular bearer.
C07D 231/14 - Composés hétérocycliques contenant des cycles diazole-1, 2 ou diazole-1, 2 hydrogéné non condensés avec d'autres cycles comportant deux ou trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou avec des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p.ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C12N 9/96 - Stabilisation d'une enzyme par formation d'un adduct ou d'une composition; Formation de conjugaisons d'enzymes
G01N 33/68 - Analyse chimique de matériau biologique, p.ex. de sang ou d'urine; Test par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligands; Test immunologique faisant intervenir des protéines, peptides ou amino-acides
99.
LONG-CYCLE-LIFE, HIGH-CAPACITY SILICON ANODES AND METHODS OF MAKING AND USING THE SAME
Materials, methods, electrodes, and devices related to high-energy-density, long-life Li-ion batteries are provided. The lithium-ion anode material contains a porous core with silicon and optionally carbon nanotubes, and a dense shell made from lithium vanadium oxide having a disordered rocksalt structure. The lithium vanadium oxide functions as a solid-state mediator layer for the anode material and overcomes the well-known problem of significant volume increase when silicon is lithiated. The lithium vanadium oxide possesses mechanical robustness and prevents electrolyte penetration. For these reasons, the anode material forms a highly stable interface with the battery electrolyte. Experimental data is presented and discussed to demonstrate embodiments of the technology. It is shown that the silicon anode material can reversibly deliver a specific capacity higher than 2500 mA·h/g. The anode material exhibits excellent cycling stability and calendar life at room temperature as well as elevated temperature.
H01M 4/38 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'éléments simples ou d'alliages
H01M 4/485 - Emploi de substances spécifiées comme matériaux actifs, masses actives, liquides actifs d'oxydes ou d'hydroxydes inorganiques d'oxydes ou d'hydroxydes mixtes pour insérer ou intercaler des métaux légers, p.ex. LiTi2O4 ou LiTi2OxFy
H01M 4/587 - Matériau carboné, p.ex. composés au graphite d'intercalation ou CFx pour insérer ou intercaler des métaux légers
H01M 10/0525 - Batteries du type "rocking chair" ou "fauteuil à bascule", p.ex. batteries à insertion ou intercalation de lithium dans les deux électrodes; Batteries à l'ion lithium
Aspects of the subject disclosure may include, for example, receiving, from a machine learning model, information about an event causing a service degradation in a cellular network, wherein the event is external to the cellular network, determining one or more event categories associated with the event causing the service degradation, determining, based on the one or more event categories, likely affected customers, the likely affected customers being likely to experience the service degradation, determining, by the machine learning model, proper resources for resolution of the service degradation, wherein the determining proper resources is based on the one or more event categories, and dispatching the proper resources for resolution of the service degradation. Other embodiments are disclosed.